The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

President Donald Trump told Fox News host Sean Hannity that the pal who starred in the "fat shot" story was "very worried" ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

WEDNESDAY, May 14, 2025 (HealthDay News) — More U.S. teenagers are getting weight-loss surgery, despite the discovery of new ...

Studies have shown that GLP-1s reduce inflammation in the brain and regulate anxiety as well as depression. When insurance ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Trump signs executive order, discussed "overweight" friend who was taking the "fat shot drug." It wasn't confirmed whether he ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.